All In Biotech

Investigational drug · Phase 2

ETX-929

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "ETX-929"

First trial start

2026

Oct 22, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ETX-929", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Non-squamous, Non-Small Cell Lung Cancer
  • Endometrial Adenocarcinoma
  • Ovarian Adenocarcinoma
  • Primary Peritoneal Carcinoma

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Endometrial cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "ETX-929" as an intervention, largest first.

All trials
  • Ensem TherapeuticsIndustry

    NCT07912593 · 320 participants (planned) · Start Oct 22, 2026 · Primary completion Oct 30, 2028

    Drug: ETX-929 dose escalation; ETX-929 dose escalation in combination with cetuximab · For: Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Non-squamous, Non-Small Cell Lung Cancer and 3 more

    Sites: Fairfax, Virginia

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Metastatic Colorectal Cancer (CRC)

  • RilogrotugPhase 31 trial

    AVEO Pharmaceuticals, Inc. · Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome

  • SSGJ-706Phase 23 trials

    Shenyang Sunshine Pharmaceutical Co., LTD. · Non Small Cell Lung Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)

  • NelmastobartPhase 22 trials

    STCube, Inc. · Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer, Non Small Cell Lung Cancer

  • DES-1357Phase 21 trial

    D. E. Shaw Research, LLC · Metastatic Colorectal Cancer (CRC)

  • HSK42360-NaPhase 21 trial

    Haisco Pharmaceutical Group Co., Ltd. · Metastatic Colorectal Cancer (CRC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.